{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:51:22Z","timestamp":1791049882062,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13550-019-0540-7","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T12:02:54Z","timestamp":1564056174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET\/CT imaging of prostate cancer"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-9058","authenticated-orcid":false,"given":"Melanie","family":"Hohberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Krapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"T\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Hammes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris D.","family":"Zlatopolskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Endepols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Neumaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"540_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]gallium-labeled PSMA ligands as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085\u20136.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"540_CR2","first-page":"1020","volume":"286","author":"R Luthi-Carter","year":"1998","unstructured":"Luthi-Carter R, Barczak AK, Speno H, Coyle JT. Molecular characterization of human brain N-acetylated \u03b1-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998;286:1020\u20135.","journal-title":"J Pharmacol Exp Ther."},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<28::AID-PROS5>3.0.CO;2-A","volume":"39","author":"CW Tiffany","year":"1999","unstructured":"Tiffany CW, Lapidus RG, Merion A, Calvin DC, Slusher BS. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate. 1999;39:28\u201335.","journal-title":"Prostate."},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull WE, W\u00e4ngler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688\u201397.","journal-title":"Bioconjug Chem."},{"key":"540_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.115.156133","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Bl\u00fcmel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a novel probe targeting prostate specific membrane antigen for Imaging and Therapy (68Ga-PSMA I&T). J Nucl Med. 2015;56:855\u201361.","journal-title":"J Nucl Med"},{"key":"540_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2967\/jnumed.112.104661","volume":"53","author":"SY Cho","year":"2012","unstructured":"Cho SY, Gage KL, Mease RC, Senthamizhchel Van S, Holt DP, Jeffrey-Kwanisai, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883\u201391.","journal-title":"J Nucl Med."},{"key":"540_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565\u201374.","journal-title":"Mol Imaging Biol."},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schom\u00e4cker K, et al. Comparison of [18F]DCFPyl and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575\u201384.","journal-title":"Mol Imaging Biol."},{"key":"540_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical relapse of prostate cancer. J Nucl Med. 2017;58:947\u201352.","journal-title":"J Nucl Med."},{"key":"540_CR10","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, et al. F-18 labeled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"540_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55\u201362.","journal-title":"Appl Radiat Isot."},{"key":"540_CR12","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-07-1517","volume":"14","author":"RC Mease","year":"2008","unstructured":"Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, et al. Synthesis and in vivo evaluation of N-[N-[[S]-1 ,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036\u201343.","journal-title":"Clin Cancer Res."},{"key":"540_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","volume":"59","author":"M Bene\u0161ov\u00e1","year":"2015","unstructured":"Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Sch\u00e4fer M, Klika KD, Mier W, Haberkorn U, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2015;59:1761\u201375.","journal-title":"J Med Chem."},{"key":"540_CR14","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1021\/jm9015813","volume":"53","author":"DE Olberg","year":"2010","unstructured":"Olberg DE, Arukwe JM, Grace D, Hjelstuen OK, Solbakken M, Kindberg GM, et al. One step radiosynthesis of 6-[18F]fluoronicotinic acid 2,3,5,6-tetraflourophenyl ester ([18F]-F-Py-TFP): a new prosthetic group for the efficient labeling of biomolecules with fluorine-18. J Med Chem. 2010;53:1732\u201340.","journal-title":"J Med Chem"},{"key":"540_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Bene\u0161ov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M, et al. Preclinical evaluation of 18F-PSMA-1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med. 2017;58:425\u201331.","journal-title":"J Nucl Med."},{"key":"540_CR16","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen Y, Pullambhatla M, Byun Y, Nimmaquadda S, Senthamizhchelvan S, Squouros G, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-urei do)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645\u201353.","journal-title":"Clin Cancer Res"},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1021\/jm800994j","volume":"52","author":"KP Maresca","year":"2009","unstructured":"Maresca KP, Hillier SM, Femia FJ, Keith D, Barone C, Joyal JL, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347\u201357.","journal-title":"J Med Chem."},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1039\/C4OB01336K","volume":"12","author":"R Richarz","year":"2014","unstructured":"Richarz R, Krapf P, Zarrad F, Urusova EA, Neumaier B, Zlatopolskiy BD. Neither azeotropic drying, nor base nor other additives: a minimalist approach to 18F-labeling. Org Biomol Chem. 2014;12:8094\u20139.","journal-title":"Org Biomol Chem."},{"key":"540_CR19","unstructured":"Neumaier B, Zlatopolskiy BD, Richarz R, Krapf P. Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer. Patent WO2016030329A1. 2014."},{"issue":"6","key":"540_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2967\/jnumed.118.218495","volume":"60","author":"Boris D. Zlatopolskiy","year":"2018","unstructured":"Zlatopolskiy BD, Endepols H, Krapf P, Guliyev M, Urusova EA, Richarz R, et al. Discovery of 18F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.118.218495 .","journal-title":"Journal of Nuclear Medicine"},{"key":"540_CR21","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E, OLINDA\/EXM. The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med."},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/rpd\/nct337","volume":"162","author":"M Andersson","year":"2013","unstructured":"Andersson M, Johansson L, Minarik D, Mattsson S, Leide-Svegborn S. An internal radiation dosimetry computer program, IDAC2.0, for estimation of patient dose for radiopharmaceuticals. Radiat Prot Dosimetry. 2013;162:299\u2013305.","journal-title":"Radiat Prot Dosimetry."},{"key":"540_CR23","doi-asserted-by":"crossref","unstructured":"Gombotz H, Zacharowski K, Spahn DR. Patient Blood Management. Thieme. 2013; pp 79-80; ISBN: 9783132410770.","DOI":"10.1055\/b-002-59191"},{"key":"540_CR24","unstructured":"syngo.via Operator Manual \u2013 syngo.MM oncology VB30. Print No. P02-005.621.01.01.02; Published by Siemens Healthcare GmbH."},{"key":"540_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewich A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"Suppl 1","key":"540_CR26","first-page":"452","volume":"59","author":"M Dietlein","year":"2018","unstructured":"Dietlein M, Hohberg M, Kobe C, Dietlein F, Zlatopolskiy B, Krapf P, et al. Performance of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET\/CT in prostate cancer patients. [abstract]. J Nucl Med. 2018;59(Suppl 1):452.","journal-title":"J Nucl Med."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13550-019-0540-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-019-0540-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T15:28:04Z","timestamp":1664033284000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-019-0540-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1186\/s13550-019-0540-7","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PET\/CT imaging was performed in compliance with the regulations of the local authorities responsible (District Administration of Cologne, Germany). All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants included in this study provided consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BN, PK, BDZ, and AD have applied for a patent on [18F]-JK-PSMA-7. The other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}